|
Arrakis Therapeutics
Arrakis Therapeutics is a biopharmaceutical company developing oral medicines that target RNA to treat a range of diseases.[1][2] The company is based in Waltham, Massachusetts, and was founded in 2015 by Jennifer Petter, now the company's Chief Innovation Officer.[3][4] In October 2016, Michael Gilman, a former Biogen executive, was named CEO.[5] In 2017, the company raised a $38 million investment from venture capital firm Canaan Partners as well as Celgene and Pfizer.[1] Arrakis was founded to focus on purposefully discovering RNA-targeting small molecule drugs.[6] Other companies had previously discovered drugs based on RNA-targeting small molecules, however, they were found opportunistically.[1] Arrakis has been able to identify RNA binding sites where small molecule drugs can bind using a bioinformatics tool.[7] The company also utilizes chemical biology tools to confirm whether their compounds are inhibiting RNA cells, and also whether the compounds are specifically targeting the disease-associated RNA.[7] In April 2019, Arrakis raised $75 million in financing to continue its development of small-molecule drugs that target RNA.[8] In April 2020, Arrakis signed a $190 million licensing agreement with Swiss multinational healthcare company Roche for exclusive rights to Arrakis' drugs developed to treat a range of diseases, including cancer.[3] In January 2022, Arrakis entered a partnership with biopharmaceutical company Amgen to develop oral drugs that target and degrade RNA. Amgen agreed to make an upfront payment of $75 million to Arrakis, with the possibility of further funding if research and development proceed as planned.[9] References
|
||||||||||||||
